thumbnail image


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文
  • Home
  • About us
    • Management
    • Living Innovation
    • Company presentation
  • Science
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News
    • News
    • Company presentation
  • Partners
    • Careers
    • Collaboration
    • Contact us
  • 搜索
    • Contact us

    • We’re Standing By
      Whether you are interested in a collaboration, career, investment opportunity or media inquiry, we’d love to hear from you. Please fill out the form below and we’ll get back to you shortly.

      Submit

      Lyvgen Shanghai

      Suite 317, Building 1, 351 Guoshoujing Road

      Lyvgen Shanghai

      Suite 601B, Building 8, 1043 Halei Road

      Lyvgen Suzhou

      Room 137, Building C36, 188 Dongping Street

      Inquiries

       

      General ----------------------------------Business Development-----------------------------Employment-------------------------------------Clinical

      info@lyvgen.com  -----------------1 bd@lyvgen.com - ------------------------------        careers@lyvgen.com    ------------------      clinical@lyvgen.com

       

      Phone +86 021-50663350

      Contact us on LinkedIn

    沪公网安备 31011502015346号
    |
    沪ICP备20018873号-2
      Home
      About us
      xLinkAb
      Contact us
    Lyvgen Biopharma Website 礼进生物 英文官网
    Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
    https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
    Cookie的使用
    我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
    了解更多